NDC 0002-6145

Baqsimi

Glucagon

Baqsimi is a Nasal Powder in the Human Prescription Drug category. It is labeled and distributed by Eli Lilly And Company. The primary component is Glucagon.

Product ID0002-6145_3928d4ab-2923-4932-91cb-d18870b0972e
NDC0002-6145
Product TypeHuman Prescription Drug
Proprietary NameBaqsimi
Generic NameGlucagon
Dosage FormPowder
Route of AdministrationNASAL
Marketing Start Date2019-07-24
Marketing CategoryNDA / NDA
Application NumberNDA210134
Labeler NameEli Lilly and Company
Substance NameGLUCAGON
Active Ingredient Strength3 mg/1
Pharm ClassesAntihypoglycemic Agent [EPC],Gastrointestinal Motility Inhibitor [EPC],Increased Gluconeogenesis [PE],Increased Glycogenolysis [PE],Decreased GI Smooth Muscle Tone [PE],Decreased GI Motility [PE],Decreased Glycolysis [PE]
NDC Exclude FlagN
Listing Certified Through2021-12-31

Packaging

NDC 0002-6145-11

1 TUBE in 1 CARTON (0002-6145-11) > 1 BOTTLE, UNIT-DOSE in 1 TUBE (0002-6145-02) > 1 POWDER in 1 BOTTLE, UNIT-DOSE (0002-6145-01)
Marketing Start Date2019-08-06
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 0002-6145-27 [00002614527]

Baqsimi POWDER
Marketing CategoryNDA
Application NumberNDA210134
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2019-08-06

NDC 0002-6145-11 [00002614511]

Baqsimi POWDER
Marketing CategoryNDA
Application NumberNDA210134
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2019-08-06

NDC 0002-6145-02 [00002614502]

Baqsimi POWDER
Marketing CategoryNDA
Application NumberNDA210134
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2019-08-09

NDC 0002-6145-01 [00002614501]

Baqsimi POWDER
Marketing CategoryNDA
Application NumberNDA210134
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitEA
Marketing Start Date2019-07-31

Drug Details

Active Ingredients

IngredientStrength
GLUCAGON3 mg/1

OpenFDA Data

SPL SET ID:3fdb4e92-2e19-487d-9f14-99871e9fd15a
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 2180671
  • 2180666
  • Pharmacological Class

    • Antihypoglycemic Agent [EPC]
    • Gastrointestinal Motility Inhibitor [EPC]
    • Increased Gluconeogenesis [PE]
    • Increased Glycogenolysis [PE]
    • Decreased GI Smooth Muscle Tone [PE]
    • Decreased GI Motility [PE]
    • Decreased Glycolysis [PE]

    NDC Crossover Matching brand name "Baqsimi" or generic name "Glucagon"

    NDCBrand NameGeneric Name
    0002-6145Baqsimiglucagon
    0002-8031Glucagonglucagon
    0548-5850GlucagonGlucagon
    43742-0252GlucagonGlucagon
    43742-0734GlucagonGlucagon
    50090-0639Glucagonglucagon
    51662-1498GLUCAGONGLUCAGON
    63083-1555GlucagonGlucagon
    63323-582GlucagonGlucagon
    63323-593GlucagonGlucagon
    63323-594GlucagonGlucagon
    63323-596GlucagonGlucagon
    64725-8031Glucagonglucagon

    Trademark Results [Baqsimi]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    BAQSIMI
    BAQSIMI
    88125097 not registered Live/Pending
    Eli Lilly and Company
    2018-09-20
    BAQSIMI
    BAQSIMI
    87828329 not registered Live/Pending
    Eli Lilly and Company
    2018-03-09
    BAQSIMI
    BAQSIMI
    86648904 5745744 Live/Registered
    ELI LILLY AND COMPANY
    2015-06-02

    © 2022 FDA.report
    This site is not affiliated with or endorsed by the FDA.